S. B. Hanauer

4.1k citations

46 papers · 3.2k indexed · 2 hit papers · h-index 20

Impact in

Genetics top 0.5%
- Inflammatory Bowel Disease
Epidemiology top 2%
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders

Papers in

Genetics 36
- Inflammatory Bowel Disease 36
- Chronic Lymphocytic Leukemia Research 7
Epidemiology 24
- Microscopic Colitis 23

Co-authors: William J. Sandborn Michael Safdi Seymour Katz P Pollack Remo Panaccione P. Rutgeerts Douglas C. Wolf Richard D. Baerg
Journals: Alimentary Pharmacology & Therapeutics (13 papers)The American Journal of Gastroenterology (6 papers)Gastroenterology (6 papers)Inflammatory Bowel Diseases (3 papers)Gut (2 papers)
Partner nations: United States Canada Belgium

In The Last Decade

S. B. Hanauer

44 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial 2007 · 798 citations

Peers

Countries citing papers authored by S. B. Hanauer

Since Specialization

Citations

This map shows the geographic impact of S. B. Hanauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. B. Hanauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. B. Hanauer more than expected).

Fields of papers citing papers by S. B. Hanauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. B. Hanauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. B. Hanauer. The network helps show where S. B. Hanauer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. B. Hanauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. B. Hanauer Line = papers co-authored together S. B. Hanauer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC Gastroenterology ·S. B. Hanauer, Silvio Danese, Jean–Frédéric Colombel, William J. Sandborn, Bruce E. Sands, Yolanda Jones-King, Sang-Joon Lee, タイフォーマハムド, Yunju Bae, Sunhee Lee, Seulgi Lee, JoonHo Lee, Jong Min Kim, Gahee Park, Joon Ho Lee, Chaeyoung Kim	2025	0
2	OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI WJ Sandborn, T. Hreus, C Gasink, (unknown), Heather Hill Vasquez, Jewel Johanns, Bruce E. Sands, S. B. Hanauer, Stephan R. Targan, Subrata Ghosh, Zhao Li-qia, Colombel Jf, Shin‐Da Lee, Levinus A. Dieleman, Seymour Katz, P. Rutgeerts, (unknown)	2016	9
3	Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol Alimentary Pharmacology & Therapeutics ·Brian G. Feagan, S. B. Hanauer, G. Coteur, Stefan Schreiber	2011	8
4	Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease Alimentary Pharmacology & Therapeutics ·S. B. Hanauer, Julián Panés, J F Colombel, Ralph Bloomfield, Stefan Schreiber, William J. Sandborn	2010	38
5	Review article: evolving concepts in treatment and disease modification in ulcerative colitis Alimentary Pharmacology & Therapeutics ·S. B. Hanauer	2008	28
6	Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans The Pharmacogenomics Journal ·Minoli A. Perera, Ranjit K. Thirumaran, Nancy J. Cox, S. B. Hanauer, Soma Das, T. Wozniewski, Vishal Lamba, Erin G. Schuetz, Mark J. Ratain, Anna Di Rienzo	2008	17
7	Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis from ACT 1 and ACT 2 The American Journal of Gastroenterology ·William J. Sandborn, P. Rutgeerts, Brian G. Feagan, Walter Reinisch, A. Olson, Jewel Johanns, Jing Lü, Daniel Rachmilewitz, S. B. Hanauer, Gary Lichtenstein, Zhao Li-qia, Daniel H. Present, Bruce E. Sands, J F Colombel	2007	2
8	Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial Gut ·William J. Sandborn, S. B. Hanauer, P. Rutgeerts, Richard N. Fedorak, (unknown), Donald MacIntosh, Remo Panaccione, Douglas C. Wolf, Jeffrey D. Kent, Zheyuan Shi, Li Ju, P Pollack Hit paper breakdown →	2007	798
9	Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease The American Journal of Gastroenterology ·William J. Sandborn, J F Colombel, P. Rutgeerts, Robert Enns, S. B. Hanauer, Remo Panaccione, Stefan Schreiber, Kathleen G. Lomax, P Pollack	2006	1
10	Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy The American Journal of Gastroenterology ·William J. Sandborn, P. Rutgeerts, Robert Enns, S. B. Hanauer, J F Colombel, Remo Panaccione, Jeffrey D. Kent, P Pollack	2006	19
11	Infliximab Therapy Improves Health Related Quality of Life in Ulcerative Colitis Patients The American Journal of Gastroenterology ·Brian G. Feagan, P. Rutgeerts, S. B. Hanauer, S. Yan, D. Eisenberg, Jewel Johanns, P. Bruinsma, William J. Sandborn	2005	2
12	Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study The American Journal of Gastroenterology ·S. B. Hanauer, William J. Sandborn, P. Rutgeerts, Richard N. Fedorak, Remo Panaccione, C. F. Doubleday, P Pollack	2005	0
13	Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial Alimentary Pharmacology & Therapeutics ·William J. Sandborn, Bruce E. Sands, Douglas C. Wolf, John F. Valentine, Michael Safdi, Seymour Katz, Kim L. Isaacs, Lawrence D. Wruble, Jeffry Katz, Daniel H. Present, Edward V. Loftus, Fiona Graeme‐Cook, Daniel J. Odenheimer, S. B. Hanauer	2003	81
14	The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis Alimentary Pharmacology & Therapeutics ·William J. Sandborn, S. B. Hanauer	2002	208
15	Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial Gastroenterology ·William J. Sandborn, S. B. Hanauer, Seymour Katz, Michael Safdi, Jourdane Eden R. Arches, Richard D. Baerg, William J. Tremaine, Marvin L. Appel, Nancy N. Diehl, A. R. Zinsmeister Hit paper breakdown →	2001	703
16	Screening and surveillance for individuals with inflammatory bowel disease Seminars in Colon and Rectal Surgery ·David T. Rubin, S. B. Hanauer	2000	2
17	Review article: safety of infliximab in clinical trials Alimentary Pharmacology & Therapeutics ·S. B. Hanauer	1999	140
18	Life-threatening complications of IBD: How to handle fulminant colitis and toxic megacolon: Clinical features, key diagnostic tests, and treatment options Robert B. Stein, S. B. Hanauer	1998	4
19	Diagnosis and medical management of inflammatory bowel disease in adults S. B. Hanauer	1993	2
20	Tumor‐associated glycoprotein (TAG‐72) expression in ulcerative colitis International Journal of Cancer ·Ann D. Thor, Boheyreh Fouladi, Jeffrey Schlom, Y. S. Kim, S. B. Hanauer	1989	35

About S. B. Hanauer

S. B. Hanauer is a scholar working on Genetics, Epidemiology, Genetics, Gastroenterology and Pharmaceutical Science, having authored 46 papers that have together received 3.2k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (36 papers), Microscopic Colitis (23 papers), Immunodeficiency and Autoimmune Disorders (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Eosinophilic Esophagitis (5 papers), Autoimmune and Inflammatory Disorders Research (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Gastrointestinal motility and disorders (3 papers). The work is most often cited by research in Genetics (2.1k citations), Epidemiology (1.6k citations), Immunology (804 citations), Hematology (416 citations) and Gastroenterology (169 citations). S. B. Hanauer has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include William J. Sandborn, Michael Safdi, Seymour Katz, P Pollack, Remo Panaccione, P. Rutgeerts, Douglas C. Wolf, Richard D. Baerg, William J. Tremaine and A. R. Zinsmeister. Their work appears in journals such as Alimentary Pharmacology & Therapeutics, The American Journal of Gastroenterology, Gastroenterology, Inflammatory Bowel Diseases and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact